September 23, 2021 -New FDA Clearance Illustrates the Utility of the i:X to Reliably Predict Pseudomonas Aeruginosa, a Bacterial Pathogen that Precludes Wound Healing and Often Evades Conventional Treatment Methods
TORONTO, CANADA – (September 23, 2021) MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial
… Read More
July 7, 2021 -Published results provides guidelines to standardize use of fluorescence imaging among wound care providers to enhance the quality of patient care
TORONTO, CANADA – (July 7 2021) MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial loads, announced the publication of an
… Read More
June 22, 2021 -LMT’s Comprehensive Sales and Support Network to Meet Significant Demand for the MolecuLight i:X® in the Wound Care Community
TORONTO, CANADA and QUEENSLAND, AUSTRALIA– (June 22, 2021) MolecuLight Inc., the leader in point-of-care fluorescence imaging for detection of wounds containing elevated bacterial loads, announces it has signed… Read More
May 18, 2021 -Results of Clinical Integration Project of MolecuLight i:X® Point-of-Care Imaging Device Illustrate Improved Access, Effectiveness and Efficiency of Wound Care
TORONTO, Ontario – (May 18, 2021) MolecuLight Inc., the leader in point-of-care fluorescence imaging for detection of wounds containing elevated bacterial loads, is helping to improve wound care in
… Read More
May 6, 2021 -Patient Wounds Documented by MolecuLight i:X Device Now Integrated with EHR Systems Through Net Health’s Tissue Analytics Platform
Pittsburgh, PA and Toronto, ON – May 6, 2021 – MolecuLight, the leader in point-of-care fluorescence imaging for real-time detection of bacteria in wounds, announced today that the company has partnered with… Read More
May 4, 2021 -Contract Awarded for Products that Bring Improvement to the Health Care Industry
PITTSBURGH, PA – (May 4, 2021) MolecuLight Corp., the leader in point-of-care fluorescence imaging for detection of wounds containing elevated bacterial loads, announces its MolecuLight i:X® fluorescence wound imaging device has received an Innovative Technology contract from
… Read More
April 8, 2021 -Distributors’ Extensive Support and Technical Expertise will Meet Growing Global Demand for the MolecuLight i:X® Fluorescence Wound Imaging Device
Toronto, Canada – (April 8, 2021) MolecuLight Inc., the leader in point-of-care fluorescence imaging for detection of wounds containing elevated bacterial loads, announced that it has appointed 11 specialized… Read More
March 9, 2021 -Leading GPO Selects MolecuLight i:X Point-of-Care Device as a Key Tool for Informing its National Long-Term Care Membership on the Presence of Elevated Bacterial Burden in Patients’ Wounds
Valley Stream, NY and Toronto, CANADA – (March 9, 2021) MolecuLight Inc., the leader in fluorescence imaging for
… Read More
March 2, 2021 -Study Reveals the Utility of Cyan Fluorescence to Reliably Predict Pseudomonas, a Bacterial Pathogen that Precludes Wound Healing and Often Evades Conventional Treatment Methods
Toronto, Canada – (March 2, 2021) MolecuLight Inc., the leader in point-of-care fluorescence imaging for point-of-care detection of wounds containing elevated bacterial
… Read More 
